![]() ![]() This additional follow-up will be needed to assess the recurrence risk over a longer time among women who paused hormone therapy, Dr. The trial participants will be followed for at least 10 years after study enrollment. ![]() These women had undergone surgery for early-stage hormone receptor (HR)-positive breast cancer and had received at least 18 months of hormone therapy. The POSITIVE clinical trial included women under age 43 who desired to become pregnant. “This is great news,” said Carlos Arteaga, M.D., who directs the University of Texas Southwestern Simmons Comprehensive Cancer Center and moderated the SABCS press conference at which the trial results were presented. ![]() A total of 365 babies were born during the study, according to results presented at the San Antonio Breast Cancer Symposium (SABCS) on December 8. Most of the 518 women in the trial became pregnant and delivered a healthy baby during the treatment pause. The study found that women could temporarily stop their hormone therapy for up to 2 years as they tried to conceive without raising the risk of a recurrence in the short term. Hormone therapy is typically given for 5 to 10 years to women who have been treated for early-stage breast cancer to help prevent the cancer from coming back. The trial focused on the use of endocrine therapy (hormone therapy), such as tamoxifen. New results from an international clinical trial may help inform these discussions. Many young women who are diagnosed with early-stage breast cancer ask their doctors about the possibility of becoming pregnant in the future. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |